A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
- Sponsor:
- TYRA Biosciences
- Sponsor Study ID:
- TYRA-300-202
- CTO #:
- 104248
- NCT Number:
- NCT06995677
- Phase:
- II
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Bladder
- Study Objectives:
- To evaluate the efficacy of TYRA-300.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Savage, Stephen, at savages@musc.edu .
- Study Coordinator, Tucker, Renee, at tuckerr@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina